GLP-1 Weight Loss Injections, Explained: What They Are, How They Work, and What the Data Actually Shows

Nearly 6 in 10 people who start a GLP-1 medication stop taking it within a year. That single number tells you almost everything you need to know about this drug class: it works, it's not simple, and going in without the right information usually ends the same way — disappointment, wasted money, or worse, a health scare.

If you've heard the names Ozempic, Wegovy, Mounjaro, or Zepbound thrown around at the gym, on the school run, or in your group chat, you've already encountered GLP-1 weight loss injections in some form. This article breaks down what they are, what the research actually says about how well they work, what they cost in side effects, and — this part matters — how to access them legally and safely, wherever you live.

I'm not a doctor, and nothing here replaces a conversation with one. But I've dug through the clinical trial data, the UK regulatory guidance, and the latest 2026 figures so you don't have to piece it together from ten different tabs.

What Are GLP-1 Weight Loss Injections?

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases naturally after you eat. It does three things: it tells your pancreas to release insulin, it slows down how fast your stomach empties, and it signals to your brain that you're full. GLP-1 receptor agonist medications are synthetic versions of that hormone, built to stick around in your bloodstream far longer than the natural version does — days instead of minutes.

That's the whole trick, really. Your body already knows how to feel full. These drugs just turn the volume up and keep it there.

The class has expanded fast. Semaglutide (sold as Ozempic for diabetes and Wegovy for weight management) was the drug that made GLP-1s a household term. Tirzepatide (Mounjaro, Zepbound) followed, acting on a second gut hormone receptor called GIP alongside GLP-1, which appears to push results further. Retatrutide adds a third hormone target, glucagon, and is currently the most potent candidate in late-stage trials. Cagrilintide works differently again — it mimics amylin, another appetite-regulating hormone — and is being tested in combination with semaglutide under the name CagriSema.

How Effective Are They, Really?

The numbers vary quite a bit by drug and dose, and it's worth sitting with the range rather than just the headline figure.

Semaglutide (Wegovy) trials showed average weight loss in the mid-teens as a percentage of starting body weight over roughly 68 weeks.

Tirzepatide users without diabetes lost around 21% of body weight on average in trial data; those with type 2 diabetes saw closer to 15%, since the underlying metabolic picture is different.

Retatrutide's Phase III TRIUMPH-1 results, reported in May 2026, showed average losses of 17.6% at the 4mg dose, 23.7% at 9mg, and 25.0% at 12mg over 80 weeks — with some participants who escalated further reaching close to 30% by 104 weeks.

Two things jump out when you compare those to older weight-loss drugs: the results are genuinely larger, and they keep improving as newer molecules target more hormone pathways at once. That's not marketing spin — it's what shows up across multiple independently reported trials.

The Side Effects Nobody Puts on the Billboard

Here's where I'll ask you a direct question: would you take a daily bout of nausea in exchange for losing a quarter of your body weight? Some people say yes without blinking. Others try it for three weeks and quit. Both reactions are common, and neither is wrong.

Gastrointestinal symptoms are the headline issue — nausea, vomiting, diarrhoea, and constipation, especially when a dose first goes up. In the retatrutide trial, nausea affected 42.4% of people at the highest dose, diarrhoea 32%, constipation 26%, and vomiting 25%. Discontinuation because of side effects ranged from about 4% at the lowest dose to over 11% at the highest.

Less common but more serious risks — including gallbladder problems, pancreatitis, and in rare cases changes to thyroid tissue seen in animal studies — are exactly the sort of thing a prescriber is meant to screen for before you ever pick up a pen. That screening step is not paperwork for its own sake. It's the difference between a medication and a gamble.

A Quick, Honest Anecdote

A friend of mine started a GLP-1 medication last year through her GP after two failed attempts at "just eating less." The first two weeks were rough — she described it as "having food poisoning on and off." By week six, the nausea had mostly settled, and by month four she'd lost close to a stone and a half. What she says stuck with her most wasn't the number on the scale, though. It was how much quieter the constant background hunger got. "I didn't realise how much of my day was spent thinking about food until it stopped," she told me. That's the appetite-signalling mechanism doing exactly what the trial data predicts — but she got there safely because a clinician was monitoring her bloodwork the whole way, adjusting her dose when side effects got heavy.

Are GLP-1 Injections Legal to Buy Without a Prescription?

No — and this is the single most important section of this article, so I'm not going to bury it.

In the UK, semaglutide and tirzepatide are licensed prescription-only medicines (POMs) under the Human Medicines Regulations. That means lawful supply requires a registered prescriber's assessment and dispensing through a regulated pharmacy — whether that's via the NHS (through specialist weight management services, generally for adults with a BMI of 30+ for semaglutide or 35+ for tirzepatide, plus a weight-related health condition) or through a private prescriber who has actually reviewed your health history.

The same principle holds broadly across the US (FDA-approved, prescription-required), Canada, Germany, and France (all EMA-regulated markets) — the drugs are effective enough to be genuinely useful, but potent enough that unsupervised use carries real risk, which is exactly why regulators everywhere have drawn the same line.

Retatrutide and cagrilintide aren't licensed for prescription at all yet in any market — they're still in clinical trials. Anything sold to you outside a trial claiming to be one of these is not a legitimate medical product.

You'll also see products marketed online as "research chemicals" or "for laboratory use only" that are, in the same breath, sold as ready-to-use injection pens with weight-loss claims attached. UK regulators have flagged this specific pattern directly: labelling something "research use" while marketing it for self-injection doesn't create a legal loophole, it just removes every safety check a real prescription would have included — no dose verification, no purity testing, no clinician watching for the rare-but-serious complications. The MHRA has documented real harm from counterfeit and unregulated GLP-1 products, including uncertain dosing and contamination. If a website is selling you a "GLP-1 injection pen kit" with no prescription requirement anywhere in the checkout, that's not a shortcut — it's the exact scenario regulators are warning people about.

Fake and Counterfeit Weight-Loss Pens: A Real, Documented Risk

This isn't a hypothetical worry. The MHRA's Yellow Card scheme logged 16 reports of falsified weight-loss pens claiming to contain semaglutide or liraglutide, and confirmed five cases where the pens actually contained insulin instead of the medication on the label. Some patients went into hypoglycaemic shock and needed emergency treatment. Separately, customs authorities seized 369 suspected fake Ozempic pens in under a year. None of that happened to people who got their prescription through the NHS or a properly regulated pharmacy — it happened through unofficial supply chains. That is the practical, documented cost of skipping the prescription step, not a theoretical one.

How to Access GLP-1 Treatment Safely

If you're considering this route, the legitimate path looks the same no matter which country you're in.

1. Start with your GP or a registered private prescriber and get a full health assessment, including bloodwork.
2. Confirm you meet the clinical criteria (BMI thresholds plus, usually, at least one weight-related condition like high blood pressure or type 2 diabetes).
3. Get your medication dispensed through a licensed pharmacy, not shipped from an unverified overseas seller.
4. Stay in contact with your prescriber as your dose changes — this is when side effects are most likely and most manageable with supervision.
5. Pair the medication with the dietary and activity changes your care team recommends; trial participants who did this saw the best-sustained results.

FAQs About GLP-1 Weight Loss Injections

Sources and Further Reading

NHS England - Weight management injections: https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/

MHRA Yellow Card findings on counterfeit weight-loss pens, via The Pharmaceutical Journal: https://pharmaceutical-journal.com/article/news/mhra-warns-of-dangers-of-fake-weight-loss-pens-after-yellow-card-reports

House of Commons Library - Weight loss medicines in England: https://commonslibrary.parliament.uk/research-briefings/cbp-10171/

Forbes Health - GLP-1 statistics and trends (2026): https://www.forbes.com/health/weight-loss/glp-1-statistics/

Peptide Authority - Tirzepatide and UK law: https://peptideauthority.co.uk/legal/tirzepatide-uk-law